Validity and representativeness of the “Disease Analyzer” patient database for use in pharmaco-epidemiological and pharmacoeconomic studies
International Journal of Clinical Pharmacology and Therapeutics2009Vol. 47(10), pp. 617–626
Citations Over TimeTop 10% of 2009 papers
Abstract
The analyses carried out in comparison with reference statistics find no indication of lack of representativeness or validity of the Disease Analyzer database. In principle, the database appears suitable for pharmacoepidemiological and pharmacoeconomic studies. Development and maintenance of large pharmacoepidemiological databases is needed for modern health services. Such databases allow assessment of health care quality and rare adverse drug effects.
Related Papers
- → Refill adherence for patients with asthma and COPD: comparison of a pharmacy record database with manually collected repeat prescriptions(2006)80 cited
- → International questionnaire study on systemic antibiotics in endodontics. Part 1. Prescribing practices for endodontic diagnoses and clinical scenarios(2021)12 cited
- → Use of lithium in the adult populations of Denmark, Norway and Sweden(2009)24 cited
- → Cotrimoxazole prescribing by dispensing and non‐dispensing doctors: do they differ in rationality?(2002)13 cited
- → Stability of individual dementia diagnoses in routine care: Implications for epidemiological studies(2022)4 cited